AusBiotech

VVMF chief executive Stephen Thompson said, "We are pleased to be working with Peter Mac to evaluate the manufacturability of this AAV-based candidate and generate the process and analytical data required to inform its future development."

Biotron has announced that Glenn Gilbert, the former chief executive and managing director of Rhythm Biosciences, will join as chief executive and executive director on 18 January 2027.

Researchers at Monash University have won more federal funding to keep studying how one of the immune system's brakes works. Their industry partner, ASX-listed biotech Immutep, is building its drug portfolio around that same mechanism.

Tofflon Science and Technology Group will show a scale model of a modular CAR-T manufacturing facility at AusBiotech International 2026 on the Gold Coast.

The PALACROS research program was formally launched in Amsterdam this week. It brings together leading European hospitals, researchers, patient organisations, and industry partners to improve treatment for patients with locally advanced pancreatic cancer.

NeuroScientific Biopharmaceuticals has announced that US regulators have largely endorsed its plans for a Phase 2 trial of a stem cell therapy in people with Crohn's disease who have not responded to existing treatments.

Perth-based regenerative medicine company Orthocell says its nerve repair device could open a new market in prostate cancer surgery.

Argent BioPharma has recast itself as an immune science company. In an update to shareholders, it said it will now focus its resources and research on inflammatory disease after licensing CannEpil to a global partner.

Racura Oncology has been given the go-ahead to raise the dose in its HARNESS-1 lung cancer trial after a safety review found no dose-limiting toxicities in the first patients treated.

A new generation of Australian life sciences innovation will take the stage on the Gold Coast this month, with AusBiotech announcing the 2026 participants in its Early-Stage Innovation Forum.

Clarity Pharmaceuticals has reached its recruitment target for the main group of the expansion phase of its SECuRE trial, and says it is already planning a registrational Phase 3 study of its copper isotope therapy for advanced prostate cancer.

An Australian company has taken one of the country's top design honours for a machine built to solve one of healthcare's most stubborn cleaning problems.